Science Competitors

Delisted . USA . 
Stock . Science 37 Holdings
SNCEDelisted Stock  USD 0.28  0.02  7.69%   
Science 37 Holdings competes with FOXO Technologies, Mangoceuticals, Common, Healthcare Triangle, EUDA Health, and HealthStream; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Science 37 competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Science 37 to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Science 37 competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Science 37's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.280.280.28
Details
Intrinsic
Valuation
LowRealHigh
0.230.230.31
Details
Naive
Forecast
LowNextHigh
0.310.310.31
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.250.270.29
Details

Science 37 Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Science 37 and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Science and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Science 37 Holdings does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
HSTM
+ 0.9
FOXO
MGRX
+ 0.81
ETAO
NRC
+ 0.8
ETAO
NRC
+ 0.78
MGRX
HSTM
+ 0.71
HCTI
AUGX
+ 0.66
AKLI
  
High negative correlations   
AKLI
- 0.93
ETAO
AUGX
- 0.76
ETAO
AKLI
- 0.75
MGRX
NRC
- 0.7
AKLI
HCTI
- 0.62
MGRX
AUGX
- 0.57
MGRX

Risk-Adjusted Indicators

There is a big difference between Science Stock performing well and Science 37 Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Science 37's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
FOXO  16.60  1.74  0.49  0.16  8.70 
(36.70)
 34.29 
(9.09)
 509.71 
ETAO  16.91 (1.41) 0.00 (0.41) 0.00 
 0.00 
 58.10 
(42.00)
 247.80 
MGRX  4.39 (0.57) 0.00 (9.18) 0.00 
 0.00 
 7.29 
(10.11)
 37.65 
HCTI  7.71  2.10  0.20  6.22  8.22 
(10.58)
 10.34 
(17.65)
 131.09 
EUDA  4.61  0.09  0.01  0.27  6.74 
(4.52)
 9.70 
(10.50)
 26.33 
ACONW  5.93  0.48  0.07  0.32  6.53 
(13.80)
 27.09 
(15.28)
 58.58 
AKLI  3.90  0.96  0.16 (4.14) 3.07 
(7.72)
 5.13 
(7.14)
 78.36 
AUGX  4.50  2.20  0.86  5.15  0.00 
(7.39)
 2.25 
(1.09)
 146.54 
HSTM  1.22  0.08  0.06  0.21  1.32 
(1.35)
 2.33 
(2.00)
 10.49 
NRC  2.00 (0.31) 0.00 (0.05) 0.00 
 0.00 
 4.51 
(4.72)
 13.17 
All Fundamental Data

Science 37 Competitive Analysis

The better you understand Science 37 competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Science 37's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Science 37's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SNCE FOXO ETAO MGRX HCTI EUDA ACONW AKLI AUGX HSTM
 7.69 
 0.28 
Science
 10.00 
 0.54 
FOXO
 0.00 
 0.05 
Etao
 6.00 
 2.65 
Mangoceuticals,
 1.87 
 1.09 
Healthcare
 3.00 
 4.53 
EUDA
 8.20 
 0.03 
Aclarion
 0.00 
 0.43 
Akili
 0.00 
 2.35 
Augmedix
 1.16 
 32.19 
HealthStream
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Very steady
Dangerous
Out of control
Very risky
Out of control
Very steady
Somewhat reliable
Very steady
Market Performance
(90 Days Performance)
Very Weak
OK
Very Weak
Very Weak
OK
Weak
OK
Very Weak
Good
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Dangerous
Very High
Below Average
Very High
High
Dangerous
Dangerous
Very Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Sell
Strong Buy
Not Available
Not Available
Not Available
Not Available
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Not Rated
Buy
Current Ratio
6.32
0.31
N/A
N/A
1.42
N/A
0.1
4.78
2.89
0.99
Net Asset
126.45 M
725 K
52.99 M
1.05 M
10.05 M
1.31 M
2.46 M
80.38 M
66.71 M
499.94 M
Profit Margin
-2.07
N/A
N/A
N/A
-0.49
N/A
N/A
N/A
-0.46
0.0684
EBITDA
(59.86 M)
(24.25 M)
(734.58 M)
(9.19 M)
(4.1 M)
(8.3 M)
(4.14 M)
(60.14 M)
(17.68 M)
59.59 M
Operating Margin
-0.6
-56.75
-0.79
-13.05
-0.46
-0.83
-103.51
-28.37
-0.64
0.0889
Current Valuation
(21.22 M)
45.05 M
10.86 M
6.78 M
7.23 M
170.68 M
N/A
(15.56 M)
113.21 M
902.11 M
Price To Book
0.67
0.91
N/A
0.49
0.87
N/A
N/A
0.35
11.09
2.75
Retained Earnings
(253.07 M)
(177.06 M)
(907.54 M)
(11.23 M)
(24.91 M)
(34.74 M)
(44.28 M)
(299.78 M)
(144.96 M)
92.37 M
Current Asset
N/A
N/A
N/A
N/A
30 K
N/A
N/A
N/A
N/A
209.54 M
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.56
2.06
1.92
N/A
0.49
-0.004
0.4
1.73
-0.19
0.35
Number Of Employees
460
N/A
3.6 K
3
22
106
4
68
1.43 K
1.08 K
Shares Outstanding
6.03 M
17.48 M
5.12 M
2.49 M
5.67 M
37.15 M
N/A
78.73 M
49.43 M
30.41 M
Cash Flow From Operations
(48.19 M)
(6.64 M)
10.82 M
(7 M)
(1.61 M)
(2.92 M)
(3.65 M)
(57.87 M)
(15.44 M)
63.97 M
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0035
Total Debt
1.32 M
4.2 M
15.41 M
128.68 K
4.32 M
3.37 M
1.13 M
15.48 M
25.85 M
23.22 M
Return On Equity
-1.19
-17.55
-11.61
-1.08
-2.88
N/A
-7.14
-0.68
-3.3
0.0565
Z Score
12.82
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.28
-1.14
-4.15
-0.58
-0.55
-0.86
-1.15
-0.37
-0.31
0.026
Number Of Shares Shorted
13.83 K
53.71 K
52.04 K
194.4 K
632.84 K
5.04 K
N/A
271.35 K
1.07 M
535.79 K
Book Value Per Share
8.69
-1.84
0.3
0.54
0.13
-0.17
-0.88
0.64
0.21
11.69
Current Liabilities
N/A
N/A
N/A
N/A
10.13 M
N/A
N/A
N/A
N/A
89.08 M
Total Asset
126.45 M
725 K
52.99 M
1.05 M
10.05 M
1.31 M
2.46 M
80.38 M
66.71 M
499.94 M
Debt To Equity
0.005
N/A
N/A
N/A
0.23
N/A
N/A
0.79
1.54
0.072
Short Ratio
0.22
0.24
0.05
0.21
0.09
0.09
N/A
0.31
5.73
3.83
Target Price
13.83
N/A
N/A
N/A
1.5
6.0
N/A
0.65
2.92
33.0
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.11
Shares Owned By Institutions
52.18
2.25
0.3
4.69
3.27
2.47
N/A
61.47
84.78
74.72
Market Capitalization
34.66 M
9.41 M
9.78 M
6.59 M
6.18 M
168.3 M
N/A
34.1 M
116.16 M
979.06 M
Price To Earning
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
87.15
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.1
Price To Sales
0.58
60.69
0.35
7.6
0.28
44.16
N/A
12.31
2.25
3.4
Net Income
(124.65 M)
(26.45 M)
(897 M)
(9.21 M)
(12.34 M)
(8.43 M)
(4.91 M)
(59.49 M)
(19.17 M)
15.21 M
Earnings Per Share
-21.4
0.05
-175.64
-5.7
-2.17
-0.62
-6.58
-0.61
-0.47
0.65
Shares Owned By Insiders
16.89
11.99
55.09
37.45
45.93
49.35
N/A
23.21
1.5
21.0
Revenue
60.26 M
145 K
58.06 M
731.49 K
33.2 M
3.71 M
75.4 K
1.68 M
44.85 M
279.06 M
Working Capital
103.03 M
(14.1 M)
(8.01 M)
607.38 K
(2.39 M)
(7.99 M)
(1.9 M)
65.06 M
33.2 M
11.85 M
Cash And Equivalents
130.24 M
18.5 M
N/A
N/A
1.36 M
N/A
452.53 K
45.62 M
29.99 M
51.84 M
Cash Per Share
1.12
5.22
N/A
N/A
0.04
N/A
0.5
0.53
0.8
1.7
Gross Profit
20.07 M
120 K
19 M
4.85 K
10.52 M
3.35 M
N/A
(118 K)
13.95 M
175.68 M
Day Typical Price
0.27
0.54
0.05
2.59
1.09
4.46
0.028
0.43
2.35
32.13
Accumulation Distribution
0.14
0.11
N/A
0.11
0.0625
0.0989
N/A
N/A
N/A
0.0222
Market Facilitation Index
0.04
0.06
N/A
0.29
0.07
0.46
N/A
N/A
N/A
0.72
Daily Balance Of Power
0.5
(1.00)
0.0
0.5172
0.2857
(0.30)
(9,223,372,036,855)
0.0
0.0
0.5139
Period Momentum Indicator
0.02
(0.06)
N/A
0.15
0.02
(0.14)
(0)
N/A
N/A
0.37
Rate Of Daily Change
1.08
0.9
1.0
1.06
1.02
0.97
0.92
1.0
1.0
1.01
Day Median Price
0.26
0.54
0.05
2.57
1.09
4.42
0.028
0.43
2.35
32.1
Price Action Indicator
0.03
(0.03)
N/A
0.16
0.015
0.04
(0)
N/A
N/A
0.27
Relative Strength Index
8.77
41.41
18.13
37.76
96.17
87.28
34.13
54.56
56.93
39.46
Coefficient Of Variation
(24,199)
851.71
(3,159)
(1,114)
827.63
3560.36
1312.09
1039.66
795.41
775.83
Mean Deviation
5.28
16.6
16.91
4.39
7.71
4.61
5.93
3.9
4.5
1.22
Jensen Alpha
0.0304
1.74
(1.41)
(0.57)
2.1
0.0913
0.4771
0.9595
2.2
0.0848
Total Risk Alpha
(1.09)
(2.31)
(6.45)
(1.54)
(0.66)
(0.81)
(0.85)
(0.61)
(0.58)
(0.06)
Sortino Ratio
N/A
0.4916
N/A
N/A
0.2016
0.0061
0.0679
0.162
0.8554
0.0558
Downside Variance
N/A
181.45
N/A
N/A
100.25
48.8
92.32
25.11
6.2
2.3
Standard Deviation
6.69
57.52
34.05
6.19
17.79
6.17
10.28
9.8
17.99
1.67
Kurtosis
0.2747
60.33
12.18
4.81
35.01
1.23
3.08
48.89
65.01
2.36
Potential Upside
11.11
34.29
58.1
7.29
10.34
9.7
27.09
5.13
2.25
2.33
Treynor Ratio
0.0668
0.1626
(0.41)
(9.18)
6.22
0.2739
0.3151
(4.14)
5.15
0.2057
Maximum Drawdown
29.72
509.71
247.8
37.65
131.09
26.33
58.58
78.36
146.54
10.49
Variance
44.72
3308.0
1159.11
38.26
316.34
38.09
105.69
95.97
323.52
2.79
Market Risk Adjusted Performance
0.0768
0.1726
(0.40)
(9.17)
6.23
0.2839
0.3251
(4.13)
5.16
0.2157
Risk Adjusted Performance
0.0057
0.0999
(0.01)
(0.06)
0.1022
0.0303
0.0677
0.083
0.106
0.1043
Skewness
0.0625
7.6
2.7
1.21
5.05
(0.62)
0.9879
6.49
8.03
0.4189
Semi Deviation
N/A
8.7
N/A
N/A
8.22
6.74
6.53
3.07
0.0
1.32
Information Ratio
(0.02)
0.1151
(0.04)
(0.11)
0.1135
0.0069
0.0635
0.0828
0.1185
0.0507
Value At Risk
(10.00)
(9.09)
(42.00)
(10.11)
(17.65)
(10.50)
(15.28)
(7.14)
(1.09)
(2.00)
Expected Short fall
N/A
(36.70)
N/A
N/A
(10.58)
(4.52)
(13.80)
(7.72)
(7.39)
(1.35)
Downside Deviation
N/A
13.47
N/A
N/A
10.01
6.99
9.61
5.01
2.49
1.52
Semi Variance
N/A
75.61
N/A
N/A
67.5
45.37
42.65
9.41
(0.63)
1.74

Science 37 Competition Performance Charts

Five steps to successful analysis of Science 37 Competition

Science 37's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Science 37 Holdings in relation to its competition. Science 37's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Science 37 in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Science 37's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Science 37 Holdings, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Science 37 position

In addition to having Science 37 in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Industrials ETFs Thematic Idea Now

Industrials ETFs
Industrials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in Science Stock

If you are still planning to invest in Science 37 Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Science 37's history and understand the potential risks before investing.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Directory
Find actively traded commodities issued by global exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY